Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells.

Zarei M, Lal S, Parker SJ, Nevler A, Vaziri-Gohar A, Dukleska K, Mambelli-Lisboa NC, Moffat C, Blanco FF, Chand SN, Jimbo M, Cozzitorto JA, Jiang W, Yeo CJ, Londin ER, Seifert EL, Metallo CM, Brody JR, Winter JM.

Cancer Res. 2017 Aug 15;77(16):4460-4471. doi: 10.1158/0008-5472.CAN-17-0015. Epub 2017 Jun 26.

2.

Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series.

Tchekmedyian N, Mudad R, Blanco FF, Raymond VM, Garst J, Erlander MG, Haura E, Berz D.

Lung Cancer. 2017 Jun;108:22-28. doi: 10.1016/j.lungcan.2017.02.010. Epub 2017 Feb 20.

PMID:
28625639
3.

Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis.

Blanco FF, Preet R, Aguado A, Vishwakarma V, Stevens LE, Vyas A, Padhye S, Xu L, Weir SJ, Anant S, Meisner-Kober N, Brody JR, Dixon DA.

Oncotarget. 2016 Nov 8;7(45):74043-74058. doi: 10.18632/oncotarget.12189.

4.

The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms.

Chand S, O'Hayer K, Blanco FF, Winter JM, Brody JR.

Int J Biol Sci. 2016 Jan 27;12(3):273-82. doi: 10.7150/ijbs.14951. eCollection 2016. Review.

5.

The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.

Blanco FF, Jimbo M, Wulfkuhle J, Gallagher I, Deng J, Enyenihi L, Meisner-Kober N, Londin E, Rigoutsos I, Sawicki JA, Risbud MV, Witkiewicz AK, McCue PA, Jiang W, Rui H, Yeo CJ, Petricoin E, Winter JM, Brody JR.

Oncogene. 2016 May;35(19):2529-41. doi: 10.1038/onc.2015.325. Epub 2015 Sep 21.

6.

Histone Deacetylase Inhibitors Activate Tristetraprolin Expression through Induction of Early Growth Response Protein 1 (EGR1) in Colorectal Cancer Cells.

Sobolewski C, Sanduja S, Blanco FF, Hu L, Dixon DA.

Biomolecules. 2015 Aug 28;5(3):2035-55. doi: 10.3390/biom5032035.

7.

Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells.

Jimbo M, Blanco FF, Huang YH, Telonis AG, Screnci BA, Cosma GL, Alexeev V, Gonye GE, Yeo CJ, Sawicki JA, Winter JM, Brody JR.

Oncotarget. 2015 Sep 29;6(29):27312-31. doi: 10.18632/oncotarget.4743.

8.

Tamoxifen prevents apoptosis and follicle loss from cyclophosphamide in cultured rat ovaries.

Piasecka-Srader J, Blanco FF, Delman DH, Dixon DA, Geiser JL, Ciereszko RE, Petroff BK.

Biol Reprod. 2015 May;92(5):132. doi: 10.1095/biolreprod.114.126136. Epub 2015 Apr 1.

9.

Novel targets in pancreatic cancer research.

Kozak G, Blanco FF, Brody JR.

Semin Oncol. 2015 Feb;42(1):177-87. doi: 10.1053/j.seminoncol.2014.12.015. Epub 2014 Dec 10. Review.

PMID:
25726061
10.

Upgrading gemcitabine with recycled kinase inhibitors.

Blanco FF, Pishvaian MJ, Brody JR.

Cell Cycle. 2014;13(18):2810-1. doi: 10.4161/15384101.2014.954211. No abstract available.

11.

PARP inhibitors for chemoprevention--letter.

Chand SN, Blanco FF, Jimbo M, Tsangaris TN, Cristofanilli M, Yeo CJ, Winter JM, Pishvaian MJ, Brody JR.

Cancer Prev Res (Phila). 2014 Nov;7(11):1170-1. doi: 10.1158/1940-6207.CAPR-14-0220. No abstract available.

12.

MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer.

Tholey RM, Lal S, Jimbo M, Burkhart RA, Blanco FF, Cozzitorto JA, Eisenberg JD, Jiang W, Iacobuzio-Donahue CA, Witkiewicz AK, Glbert M, Yeo CJ, Brody JR, Sawicki JA, Winter JM.

Mol Cancer Res. 2015 Mar;13(3):439-48. doi: 10.1158/1541-7786.MCR-14-0199. Epub 2014 Oct 21.

13.

Transforming growth factor β regulates P-body formation through induction of the mRNA decay factor tristetraprolin.

Blanco FF, Sanduja S, Deane NG, Blackshear PJ, Dixon DA.

Mol Cell Biol. 2014 Jan;34(2):180-95. doi: 10.1128/MCB.01020-13. Epub 2013 Nov 4.

14.

Mechanistic aspects of COX-2 expression in colorectal neoplasia.

Dixon DA, Blanco FF, Bruno A, Patrignani P.

Recent Results Cancer Res. 2013;191:7-37. doi: 10.1007/978-3-642-30331-9_2. Review.

15.

The role of tristetraprolin in cancer and inflammation.

Sanduja S, Blanco FF, Young LE, Kaza V, Dixon DA.

Front Biosci (Landmark Ed). 2012 Jan 1;17:174-88. Review.

16.

The roles of TTP and BRF proteins in regulated mRNA decay.

Sanduja S, Blanco FF, Dixon DA.

Wiley Interdiscip Rev RNA. 2011 Jan-Feb;2(1):42-57. doi: 10.1002/wrna.28. Review.

17.

High serum prolactin levels in asymptomatic HIV-infected patients and in patients with acquired immunodeficiency syndrome.

Graef AS, Gonzalez SS, Baca VR, Ramirez ML, Daza LB, Blanco FF, Ortiz OA, Lavalle CM.

Clin Immunol Immunopathol. 1994 Sep;72(3):390-3.

PMID:
8062450

Supplemental Content

Loading ...
Support Center